Enclomiphene for Men: How It Works, Who It's For, and the Risks

Enclomiphene is an oral medicine that blocks estrogen’s signal in the brain. The pituitary responds by releasing more LH and FSH, the two hormones that tell your testes to make testosterone and sperm. So instead of replacing testosterone from outside, the way testosterone replacement therapy (TRT) does, enclomiphene pushes your body to make more of its own, and sperm production usually keeps going. It isn’t FDA-approved, and it only works if your pituitary and testes can still respond. Whether it fits you is a call for a provider, after a proper history and morning labs.

If you’ve read our guide to Clomid for men, a lot of this will sound familiar. This post covers what’s specific to enclomiphene: what it is, how it compares, who it may suit, what the research shows and where regulators stand.

What is enclomiphene?

Clomiphene citrate (brand name Clomid) is a mix of two mirror-image forms of the same molecule, called isomers. Enclomiphene is one of those two forms, separated out on its own. The Department of Defense’s Operation Supplement Safety program describes it as a component of clomiphene. Clomiphene itself is FDA-approved only to help women ovulate.

The mechanism works in four steps:

1. Your hypothalamus and pituitary keep track of estrogen in your blood. When they sense enough, they ease off the signals that drive your testes.
2. Enclomiphene blocks estrogen receptors in that feedback center, so the brain reads less estrogen than is really there.
3. The pituitary answers by releasing more luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
4. LH tells the testes to make more testosterone. FSH supports sperm production.

Because it works by turning up your own system, enclomiphene only helps when that system can respond. That’s why the cause of low testosterone matters so much, and why we evaluate before we treat. Our overview of men’s hormone health shows how these pieces fit together.

Enclomiphene vs. Clomid vs. TRT

Table sources: the Clomid FDA label, the Kim et al. phase III trials and Operation Supplement Safety.

Put simply, enclomiphene and Clomid restart your own production, while TRT replaces it. If you’re planning a family now or soon, that difference matters. Our post on fertility after testosterone treatment explains why TRT and conception often don’t mix, and our TRT page covers how replacement works when it is the right choice.

Who enclomiphene may be a fit for

Enclomiphene has mainly been studied in men with secondary hypogonadism, where the testes are healthy but the brain isn’t sending a strong enough signal. Our page on secondary hypogonadism explains that pattern.

A provider might bring up enclomiphene, or a related option, when a man has:

• Symptoms of low testosterone plus low morning testosterone confirmed on a repeat test
• Low or low-normal LH and FSH, which points to a signaling problem rather than failing testes
• A wish to keep his fertility, now or later, which makes TRT a poor first choice
• No other fixable cause behind the low reading, such as untreated sleep apnea, a medication effect or a pituitary problem that needs its own workup

Many men with borderline levels also have room to improve through sleep, weight and training. Our posts on sleep and testosterone and weight training and testosterone cover what helps. Medication isn’t always the first step.

Not sure whether your low testosterone starts in the testes or the brain? A hormone evaluation with morning labs is how we find out. See what a low T evaluation involves

Who it’s not for

Enclomiphene can’t fix a problem it can’t reach. It’s generally not a fit for:

• Primary hypogonadism. When the testes themselves aren’t working, LH and FSH are usually already high, and pushing them higher does little. See our page on primary hypogonadism.
• Untreated pituitary disease. A pituitary tumor or high prolactin has to be found and managed first.
• A history of blood clots. European regulators cited the risk of clots in the veins when they refused an enclomiphene product (more on that below).
• Vision changes on clomiphene-type drugs. The Clomid label tells patients with visual symptoms to stop treatment and get an eye exam.

That isn’t a complete list. Your own history, medications and labs decide what’s appropriate, which is why a provider has to make the call.

What to expect

In the phase III trials published by Kim and colleagues, overweight men with secondary hypogonadism took enclomiphene or testosterone gel for 16 weeks. Testosterone rose in every treatment group. LH and FSH went up with enclomiphene and down with the gel. Sperm concentration stayed in the normal range on enclomiphene, while the gel group saw a marked drop.

A 2025 meta-analysis of 10 randomized trials covering 819 men, by Hohl and colleagues, found that clomiphene or enclomiphene raised total testosterone compared with placebo. Levels were similar to testosterone gel, and sperm concentration was higher than with gel. Symptom results were mixed: some trials showed better sexual desire or symptom scores, others found no difference from placebo. The testosterone benefit was also smaller in older and heavier men.

In practice, that means three things:

• Labs change before you feel different. Your provider will usually recheck testosterone and related hormones within the first several weeks. Changes in energy, libido and mood, if they come, tend to lag behind the numbers.
• Sperm takes longer. Semen results are usually judged over about three months, because that’s how long sperm take to develop.
• Responses vary. Nobody can promise a testosterone number, a symptom change or a fertility outcome. Some men respond well, some modestly and some not at all.

Side effects and risks

There isn’t much long-term safety research on enclomiphene, and the Hohl meta-analysis called its own safety data underpowered. Risks a provider will go over include:

• Vision changes. The Clomid label warns of blurring, spots or flashes, and prolonged visual problems have been reported. Any vision change is a reason to stop and call your provider.
• Rising estradiol. In the meta-analysis, estradiol ran higher on clomiphene or enclomiphene than on placebo or gel. In some men that can mean breast tenderness. Our page on hormonal imbalance in men explains why the testosterone-to-estrogen balance matters.
• Headache and mood changes. These are reported with clomiphene-type drugs, as our Clomid post notes.
• Blood clots. The European Medicines Agency named clots in the veins as a risk when it refused authorization.
• Blood count and PSA changes. In one trial in the meta-analysis, men stopped treatment because their hematocrit or PSA went up.

How enclomiphene is monitored

If enclomiphene or a similar medicine is part of your plan, follow-up labs aren’t optional. A typical panel includes:

• Total testosterone, plus free testosterone when SHBG is off
• LH and FSH, to confirm the pituitary is responding
• Estradiol, ideally with a sensitive test
• CBC, including hematocrit
• PSA, based on your age and risk
• Semen analysis, if fertility is a goal

Our page on comprehensive hormone testing shows what a full panel covers and how to prepare for a morning draw.

Is enclomiphene FDA approved?

No. Operation Supplement Safety states that enclomiphene “has not been approved by FDA for any use” and that its development as a drug was discontinued in 2021.

Regulators have looked at it more than once:

• Europe, 2018. The European Medicines Agency refused marketing authorization for EnCyzix, an enclomiphene product. It concluded the benefits didn’t outweigh the risks, noting that the studies didn’t measure benefits men would feel, such as libido, bone strength or erections, and that there was a risk of blood clots.
• United States, 2022. The FDA proposed leaving enclomiphene citrate off its list of bulk substances pharmacies may use for compounding under section 503A. Its Pharmacy Compounding Advisory Committee then voted 8 to 4 against adding it, with members pointing to a lack of evidence that it works clinically.

Enclomiphene sold in the U.S. is generally compounded. FDA warning letters state that “compounded drug products are not FDA-approved”, which means the FDA hasn’t reviewed them for safety, effectiveness or quality. Be wary of any website that sells enclomiphene without an exam and labs, or calls it a supplement. It’s a prescription drug, not a dietary supplement.

Enclomiphene is one option, not the starting point

Depending on your labs and goals, a provider may also talk through clomiphene, hCG, lifestyle changes or TRT. Our page on fertility-preserving testosterone treatment covers the options that keep sperm production going, and our page on low testosterone and fertility explains how the two connect. We also explain why we don’t start most men on testosterone injections.

Hormone and fertility evaluation in Houston

The Y Factor evaluates low testosterone and male fertility at two clinics: Memorial on the Katy Freeway and The Woodlands. Men come to us from across the area, including Katy and Cypress. Every evaluation starts in person with a history, an exam and morning labs, so the plan is built on the cause rather than a guess.

If you’re thinking about children in the next few years, say so at the first visit. It changes which options are on the table.

Want to know whether a fertility-preserving option like enclomiphene is right for you? Start with an in-person hormone evaluation and morning labs. Book a hormone evaluation